LTRN stock news · Lantern Pharma
Get alerts for LTRN
Follow Lantern Pharma (LTRN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LTRNFree on the App Store and Google Play, or on the web.
Lantern Pharma shared updates for Q3 2026, showing progress in its cancer treatment projects using AI.
NeutralLantern Pharma reported continued work on its cancer-drug research, with no financial results or measured surprises. The update does not change its outlook.
Lantern Pharma Inc. has been told it might be removed from Nasdaq for not meeting listing rules.
Bad for LTRNLantern Pharma failed Nasdaq listing tests after its listed securities stayed below a required value. It has 180 days to fix the problem or risk removal.
12 health care stocks changed a lot in prices after the market closed on Tuesday.
NeutralThe article reports Lantern Pharma shares fell 7%, but gives no company news behind the move. It does not change the business outlook.
Lantern Pharma Inc. says it will hold a live webinar about its AI drug development on September 23, 2026.
NeutralLantern filed a notice about a webinar on its Open-Medicine AI platform; the filing reported no financial or operational results, so the reading of LTRN is unchanged.